Welisch Eva, Cherlet Eric, Crespo-Martinez Eugenia, Hansky Bert
Department of Pediatric Cardiology, Ruhr University Bochum, North Rhine Westphalia, Germany.
Pacing Clin Electrophysiol. 2010 Sep;33(9):1112-8. doi: 10.1111/j.1540-8159.2010.02781.x.
With the development of new technical devices and software more appropriate for pediatric patients, pacemaker implantations in children and young adults have increased over time. It is necessary to monitor the mid- and long-term consequences. The decision for the implantation of a cardiovertor defibrillator (ICD) in children remains challenging despite technical improvements.
To assess the safety of pacemaker implantation in children, to review old and new indications, and to point out changes of management over time.
Between 1984 and 2009, 181 patients required the implantation of a pacemaker or an ICD device at the Heart and Diabetes Centre in Bad Oeynhausen, Germany. Their charts have been reviewed pro- and retrospectively for indications, complications, longevity of the device, and the natural course.
Indications have been high-degree atrioventricular block in 65% (postoperative 55%) and sinus node dysfunction in 24% (postoperative 90%), including three patients with vasovagally mediated significant bradycardia. Eleven percent required the implantation of an ICD device secondary to significant ventricular arrhythmias. The indication was class II in one-third of all patients. Complications requiring revision occurred in six patients (3.3%); one of them required removal of the device due to an infection. Ten patients died, but none related to pacemaker implantation.
Pacemaker implantation even in young pediatric patients is generally safe. No complication led to the death of a patient. The number of class II indications has been increasing. The future aim is to improve pediatric algorithms and to prevent unnecessary pacing.
随着更适合儿科患者的新技术设备和软件的发展,儿童和青少年起搏器植入术的数量随时间有所增加。有必要监测其中长期后果。尽管技术有所改进,但儿童植入心脏复律除颤器(ICD)的决策仍然具有挑战性。
评估儿童起搏器植入的安全性,回顾新旧适应证,并指出管理方式随时间的变化。
1984年至2009年期间,德国巴特奥伊瑙森心脏与糖尿病中心有181例患者需要植入起搏器或ICD设备。对他们的病历进行了前瞻性和回顾性审查,以了解适应证、并发症、设备使用寿命和自然病程。
适应证包括65%的高度房室传导阻滞(术后为55%)和24%的窦房结功能障碍(术后为90%),其中包括3例血管迷走性介导的严重心动过缓患者。11%的患者因严重室性心律失常需要植入ICD设备。所有患者中有三分之一的适应证为Ⅱ类。6例患者(3.3%)出现需要翻修的并发症;其中1例因感染需要取出设备。10例患者死亡,但均与起搏器植入无关。
即使是年幼的儿科患者,起搏器植入总体上也是安全的。没有并发症导致患者死亡。Ⅱ类适应证的数量一直在增加。未来的目标是改进儿科算法并防止不必要的起搏。